NCT06504381 2026-03-11
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Phase 1/2 Recruiting
Clinical Trials
18 trialsNCT06264388 2025-05-29
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
University of Miami
Phase 2 Recruiting
NCT06562621 2024-08-20
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
Phase 1/2 Completed
NCT03724071 2023-06-23
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
Transgene
Phase 1/2 Terminated
NCT04194034 2023-06-23
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
Transgene
Phase 1/2 Terminated
NCT02015819 2021-10-20
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Completed
NCT01562626 2021-05-12
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
Anaeropharma Science, Inc.
Phase 1/2 Suspended
NCT04195373 2020-11-25
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Themis Bioscience GmbH
Phase 1 Withdrawn
NCT04089163 2020-03-30
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Tocagen Inc.
Phase 1 Withdrawn
NCT04327011 2020-03-30
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Tocagen Inc.
Phase 1 Terminated
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT01156584 2018-05-21
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
Tocagen Inc.
Phase 1 Completed
NCT01470794 2018-05-21
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Tocagen Inc.
Phase 1 Completed
NCT01985256 2018-05-21
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Tocagen Inc.
Phase 1 Completed
NCT01172964 2017-11-09
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
City of Hope Medical Center
Phase 1 Completed
NCT03294486 2017-11-06
ONCOVIRAC
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Unknown
NCT00978107 2014-07-16
Trial of TG4023 Combined With Flucytosine in Liver Tumors
Transgene
Phase 1 Completed